2023-509132-26-00招募中1 期
A study to investigate safety of INT2104 infusions in participants aged 18 years of age and older who have B-cell cancers that came back after previous treatment [INVISE]
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 12
- 试验地点
- 5
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
EU CT Support
Scientific
Interius Biotherapeutics Inc.
研究点 (5)
Loading locations...
相似试验
招募中
1 期
JMT106 Injection in the Treatment of Advanced Solid TumorsHepatocellular CarcinomaLung Squamous Cell CarcinomaNCT07275073Shanghai JMT-Bio Inc.200
招募中
2 期
INJECTABL-II trial: Dose finding, efficacy and immunological response of a novel immuno-adjuvant (IP-001) following microwave ablation or irreversible electroporation for colorectal liver metastases.2023-504572-25-00Amsterdam UMC119
尚未招募
1 期
A Study to Evaluate the Pharmacokinetics and Food-effect of IN-M00002 Tablet in Healthy Adult VolunteersNCT07277712HK inno.N Corporation74
招募中
2 期
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION582 in Patients with Angelman SyndromeAngelman syndrome2024-512589-32-00Ionis Pharmaceuticals Inc.4
招募中
2 期
ATA-100 gene therapy trial in patients with limb-girdle muscular dystrophy2023-506677-36-00Atamyo Therapeutics, Atamyo Therapeutics20